Reports
The growth in the generics industry
During 2010 there was unprecedented activity in the pricing and market access landscape, much of which has aided the growth in the generics industry during 2010. This activity occurred across three broad themes:
Patent cliff and the generics industry
An estimated US$186 billion in sales revenues of patent-protected medicines is likely to be exposed to generic competition between now and 2016 [1].
A sustainable generics industry in the EU
Today, generic medicines play an essential role in treating disease by increasing the accessibility and affordability of modern day pharmaceuticals. It is therefore essential to ensure that generics can enter the market as soon as possible after patent and data exclusivity protections expire and compete effectively in order to maintain a sustainable generics industry.
Generics grab 80% share of US market and fill 78% of prescriptions
As more brand-name drugs lose patent protection, use of less expensive generics continues to rise. A new report, published in April 2011 by IMS Health, shows a slowdown in US spending on drugs, but an increase in the percentage of prescriptions filled by generics and a faster rate of capture of market share by generics after patent expiry.
Global pharmaceutical growth predicted to be 5–7% in 2011
According to IMS Health, global drug sales will rise in 2011 despite patent losses. Although patent expirations and limits on drug spending can hamper growth of drug sales in developed countries, global pharmaceutical sales are nonetheless expected to grow 5–7% in 2011, compared with 4–5% growth in 2010, according to an annual forecast by IMS Health.
The EU and rational use of medicines
A report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) surveyed measures for promoting the rational use of medicines in the 27 EU Member States.
The Netherlands and rational use of medicines
The Netherlands was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU Member States.
Promoting rational use of medicines in Europe
In a report by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute), measures for promoting the rational use of medicines in the 27 EU Member States were surveyed.
Germany’s rational use of medicines
Germany was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU Member States.
Italy’s rational use of medicines
Italy was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU member states.
